Affinage

IGF2BP3

Insulin-like growth factor 2 mRNA-binding protein 3 · UniProt O00425

Length
579 aa
Mass
63.7 kDa
Annotated
2026-06-10
100 papers in source corpus 58 papers cited in narrative 58 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

IGF2BP3 is an oncofetal RNA-binding protein that acts principally as an N6-methyladenosine (m6A) reader, recognizing m6A-marked transcripts to control their stability, translation, and processing across oncogenic, metabolic, immune, and developmental programs (PMID:35197058, PMID:39198433, PMID:40328743). Its KH domains mediate direct binding to target mRNAs, and the first KH domain carries a regulatory ubiquitination site (K213) whose modification by the E3 ligase Parkin triggers proteasomal degradation and abolishes the protein's m6A-reader oncogenic function (PMID:37877353). The dominant output of m6A recognition is transcript stabilization: IGF2BP3 prolongs the half-life of oncogenic and metabolic mRNAs including MYC and CDK6 (PMID:26974154), CCND1 (PMID:32993738), PD-L1 (PMID:35197058), and serine-synthesis genes ATF4/PHGDH/PSAT1 (PMID:40328743), thereby driving proliferation, immune evasion, and metabolic reprogramming. The same reader activity desensitizes tumor cells to ferroptosis by stabilizing anti-ferroptotic transcripts such as NRF2, GPX4, and SLC3A2 (PMID:36030651, PMID:36457846). Beyond stabilization, IGF2BP3 also binds internal m7G modifications and, in contrast to its m6A role, promotes degradation of m7G-marked transcripts including TP53 (PMID:39198433), and can destabilize select m6A targets through partnership with ribonucleases XRN2 and the exosome (PMID:26522719). IGF2BP3 additionally protects specific transcripts from miRNA/RISC-mediated repression by occupying or overlapping microRNA binding sites (PMID:27210763, PMID:30797711), localizes target mRNAs to cytoplasmic RNA granules in membrane protrusions for local translation during invasion (PMID:25216519), and in development stabilizes maternal mRNAs and, with Lin28b, governs the fetal-to-adult hematopoietic switch (PMID:31221665, PMID:32127635). Its abundance is itself heavily regulated by competing E3 ligases (HECTD4, TRIM21, MIB1-linked pathways) and by metabolic lactylation that retunes its target repertoire (PMID:35031058, PMID:36822301, PMID:39450426). Loss-of-function in mouse and zebrafish models confirms requirements in leukemogenesis, germ-cell and maternal-to-zygotic transition control, and tissue regeneration (PMID:34321607, PMID:34214072, PMID:37188676).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2015 High

    Established that IGF2BP3 does not act in isolation but couples to ribonucleases to destabilize select transcripts, an early indication that the protein controls mRNA turnover bidirectionally rather than acting only as a stabilizer.

    Evidence RIP-seq plus co-IP with XRN2 and exosome components and depletion rescue in cancer cells

    PMID:26522719

    Open questions at the time
    • Did not establish whether ribonuclease recruitment depends on RNA modification status
    • Generality across target classes unclear
  2. 2016 High

    Defined direct oncogenic targets and an unconventional regulatory mode: IGF2BP3 stabilizes MYC/CDK6 via 3'UTR elements and shapes miRNA-RISC engagement, linking it to proliferation, survival, and invasion.

    Evidence CLIP-seq and iCLIP with knockdown/enforced expression and in vivo bone marrow and invasion assays

    PMID:26974154 PMID:27210763

    Open questions at the time
    • Whether m6A drives target selection was not yet addressed
    • Mechanism of RISC promotion vs. protection not resolved
  3. 2017 High

    Extended IGF2BP3 function beyond mRNA to a noncoding RNA target, showing it protects 7SK RNA to restrain P-TEFb and control developmental cell-fate transitions.

    Evidence Knockdown in neonatal megakaryocyte progenitors with phenotypic and 7SK stability assays

    PMID:28481226

    Open questions at the time
    • Binding determinants on 7SK not defined
    • Whether m6A or other marks mediate 7SK recognition unknown
  4. 2019 High

    Placed IGF2BP3 within a Lin28b partnership and autoregulatory loop that stabilizes thousands of mRNAs, explaining its role in the fetal-adult hematopoietic switch.

    Evidence Proteomics, in situ interaction analysis, scRNA-seq, and enforced co-expression in adult HSPCs

    PMID:31221665

    Open questions at the time
    • Direct vs. indirect Lin28b binding interface not mapped
    • Relative contribution of each partner to stabilization unclear
  5. 2020 Medium

    Crystallized the central paradigm that IGF2BP3 is an m6A reader stabilizing modified transcripts (CCND1, VEGF), connecting modification recognition to cell cycle and angiogenesis control.

    Evidence RIP/MeRIP with cell cycle and rescue assays; parallel maternal mRNA stabilization in zebrafish mutants

    PMID:32127635 PMID:32993738

    Open questions at the time
    • Quantitative binding affinity for m6A vs. unmodified sites not measured here
    • Reader activity vs. stabilizer-protein recruitment not separated
  6. 2021 High

    Genetic deletion demonstrated causal requirement in leukemia and revealed an unexpected role in pre-mRNA splicing, broadening function beyond mRNA stability.

    Evidence Igf2bp3 knockout in MLL-Af4 mouse leukemia with RNA-seq, splicing analysis, and survival

    PMID:34321607

    Open questions at the time
    • Mechanism of splicing regulation not defined
    • Whether nuclear vs. cytoplasmic pools drive distinct outputs unresolved
  7. 2022 High

    Connected IGF2BP3 m6A reading to immune evasion and ferroptosis resistance, establishing it as a node where mRNA modification controls the tumor microenvironment and cell-death sensitivity.

    Evidence MeRIP-seq/RIP-qPCR for PD-L1 and anti-ferroptotic transcripts with xenograft and ferroptosis readouts

    PMID:35197058 PMID:36030651 PMID:36457846

    Open questions at the time
    • Whether a single binding mode governs all these targets unknown
    • Context dependence of target selection not addressed
  8. 2023 High

    Identified post-translational control of IGF2BP3 abundance, showing Parkin ubiquitinates K213 in KH1 to trigger degradation and that diverse circRNAs shield it from competing E3 ligases, linking protein stability to its oncogenic activity.

    Evidence In vitro/in vivo ubiquitination assays, MS site mapping, functional mutagenesis, and circRNA pull-down/Co-IP with HECTD4 and TRIM25

    PMID:35031058 PMID:37340423 PMID:37877353

    Open questions at the time
    • Full E3 ligase repertoire and deubiquitinases incomplete
    • How modification at K213 alters RNA binding structurally not shown
  9. 2024 High

    Revealed modification-specific bifunctionality and metabolic input: IGF2BP3 reads internal m7G to degrade transcripts including TP53, while glycolysis-driven lactylation retunes its target capture in metabolic reprogramming.

    Evidence In vitro binding, dCas13b-guided site-specific m7G targeting, half-life assays, and lactylation modification/RIP assays

    PMID:39198433 PMID:39450426

    Open questions at the time
    • Structural basis for opposing m6A vs. m7G outcomes unknown
    • How lactylation alters domain function not defined
  10. 2024 High

    Demonstrated that IGF2BP3 sustains serine and other metabolic programs through m6A stabilization, providing a therapeutic vulnerability via combined silencing and dietary restriction.

    Evidence CRISPR screen, RIP, mRNA stability assays, and dietary restriction in AML mouse models

    PMID:40328743

    Open questions at the time
    • Selectivity for metabolic over other targets not mechanistically explained
    • Normal-tissue dependence beyond hematopoiesis not mapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single reader discriminates among m6A (stabilizing), m7G (destabilizing), and ribonuclease-coupled fates on different transcripts, and what structural or PTM state dictates each outcome, remains unresolved.
  • No structural model linking domain occupancy to opposing transcript fates
  • Rules governing partner (XRN2, exosome, HuR, stabilizer) selection unknown
  • Quantitative competition between stabilizing and degradative modes uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 5 GO:0098772 molecular function regulator activity 3 GO:0140098 catalytic activity, acting on RNA 2
Localization
GO:0005634 nucleus 1 GO:0005829 cytosol 1 GO:0031410 cytoplasmic vesicle 1
Pathway
R-HSA-8953854 Metabolism of RNA 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1430728 Metabolism 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 2
Partners
ILF3LIN28BMETTL14NONOPARK2PTBP1TRIM25XRN2

Evidence

Reading pass · 58 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 IGF2BP3 modulates miRNA-mRNA interactions by promoting association of the RNA-induced silencing complex (RISC) with specific transcripts in pancreatic ductal adenocarcinoma cells; iCLIP revealed significant overlap of IGF2BP3 and microRNA binding sites, and loss of IGF2BP3 reduced cell invasiveness and remodeled focal adhesion junctions. iCLIP (individual nucleotide resolution crosslinking immunoprecipitation), genome-wide approaches, loss-of-function assays Cell reports High 27210763
2016 IGF2BP3 directly targets oncogenic transcripts MYC and CDK6 via elements within 3' UTRs to stabilize them, promoting hematopoietic progenitor proliferation and survival; enforced IGF2BP3 expression in mice enhanced Myc and Cdk6 expression in bone marrow. Cross-link immunoprecipitation and high-throughput sequencing (CLIP-seq), knockdown/enforced expression in murine BM cells, in vivo mouse model The Journal of clinical investigation High 26974154
2015 IGF2BP3 destabilizes EIF4E-BP2 and MEIS3 mRNAs through interaction with ribonucleases XRN2 and exosome components (co-IP), thereby facilitating eIF4E-mediated translational activation and promoting cell proliferation. RNA immunoprecipitation followed by massively parallel sequencing, co-immunoprecipitation with XRN2 and exosome components, IGF2BP3 depletion rescue experiments Oncogene High 26522719
2014 IGF2BP3 and IGF2BP3-bound transcripts (ARF6 and ARHGEF4) localize to cytoplasmic RNA granules accumulating in membrane protrusions of pancreatic cancer cells, where they are preferentially translated to induce further protrusion formation, promoting cell invasiveness and tumor metastasis. Subcellular fractionation/localization imaging, translation assays in membrane protrusions, in vivo metastasis model Oncotarget Medium 25216519
2017 IGF2BP3 (neonatal-specific expression) prevents destabilization of nuclear RNA 7SK, thereby blocking P-TEFb activation in neonatal megakaryocytes and restricting adult-type megakaryocyte morphogenesis; IGF2BP3 knockdown conferred adult-type phenotypic and molecular features on neonatal megakaryocytes. Knockdown in neonatal progenitors, phenotypic assays (polyploidization, proplatelet formation), molecular analysis of 7SK RNA stability The Journal of clinical investigation High 28481226
2019 Lin28b directly interacts with IGF2BP3 (shown by proteomics and in situ analyses), and together they stabilize thousands of mRNAs including Pax5 and Arid3a by binding at the same sites; IGF2BP3 mRNA itself is a target, forming an autoregulatory loop that mediates fetal-adult hematopoietic switch. Proteomics, in situ interaction analyses, single-cell RNA sequencing, enforced co-expression in adult HSPCs Genes & development High 31221665
2021 IGF2BP3 regulates a posttranscriptional operon in MLL-Af4 leukemia, controlling steady-state mRNA levels of Hoxa locus genes and Ras signaling pathway transcripts, and unexpectedly also regulates pre-mRNA splicing; Igf2bp3 deletion significantly increases survival of MLL-Af4 leukemia mice. Genetic deletion (Igf2bp3 knockout) in mouse leukemia model, RNA-seq, splicing analysis, in vivo survival assay Leukemia High 34321607
2016 IMP-3/IGF2BP3 and its protein partners ILF3/NF90 and PTBP1 bind to the 3'UTRs of cyclin D1, D3 and G1 mRNAs and protect them from translational repression induced by miRNA-dependent recruitment of AGO2/GW182 complex; this regulation depends on nuclear localization of IMP-3. Knockdown experiments, polyribosome association assays, co-immunoprecipitation with AGO2/GW182 International journal of oncology Medium 27840950
2019 IGF2BP3 competitively occupies the miR-3614-3p binding site on TRIM25 mRNA 3'UTR and inhibits miR-3614 maturation, thereby protecting TRIM25 mRNA from miR-3614-mediated degradation and promoting breast cancer cell proliferation. Luciferase activation assays, RNA immunoprecipitation (RIP), biotin pull-down assays, in vitro and in vivo loss/gain-of-function EBioMedicine Medium 30797711
2020 In zebrafish, Igf2bp3 maintains maternal mRNA stability prior to the maternal-to-zygotic transition; depletion of maternal igf2bp3 destabilizes maternal mRNAs and causes abnormal cytoskeleton organization and cell division, while overexpression enhances stability of target maternal mRNAs. Maternal igf2bp3 mutant zebrafish, mRNA stability assays, GO analysis, overexpression experiments Communications biology High 32127635
2021 In zebrafish, Igf2bp3 loss leads to expanded yolk syncytial layer, reduced germline RNA expression, translational de-regulation of a Nodal reporter during mid-blastula transition, and defects in primordial germ cell behavior and germ cell death; adult igf2bp3 mutants show strong male bias. Igf2bp3 maternal/zygotic mutants, Nodal reporter assay, RNA/PGC analysis, adult phenotype assessment PLoS genetics High 34214072
2022 METTL3-mediated m6A modification of PD-L1 mRNA is read by IGF2BP3, which stabilizes PD-L1 mRNA; IGF2BP3 knockdown reduced PD-L1 mRNA stability and enhanced anti-tumor T cell activity in vitro and in vivo. MeRIP-seq, MeRIP-qPCR, RIP-qPCR, m6A quantification, xenograft mouse models, knockdown experiments Molecular cancer High 35197058
2020 IGF2BP3 acts as an m6A reader that binds to m6A-modified CCND1 mRNA in its CDS region to regulate mRNA stability, and similarly reads m6A modification on VEGF mRNA to regulate its stability; knockdown of IGF2BP3 repressed S-phase entry and angiogenesis in colon cancer. RNA immunoprecipitation (RIP), m6A RNA immunoprecipitation (MeRIP), cell cycle flow cytometry, rescue experiments with CCND1 overexpression Journal of experimental & clinical cancer research Medium 32993738
2022 IGF2BP3 interacts with RCC2 mRNA and stabilizes m6A-modified RCC2 mRNA in AML cells; IGF2BP3 knockdown suppressed AML cell survival, proliferation, and leukemic capacity in vitro and in vivo. RNA immunoprecipitation, m6A modification assays, knockdown in AML cell lines, in vivo leukemia models Experimental & molecular medicine Medium 35217832
2023 Parkin (E3 ubiquitin ligase) directly interacts with IGF2BP3 and ubiquitinates it at K213 in the first KH domain, leading to proteasomal degradation; K213 mutation abolishes IGF2BP3's oncogenic function as an m6A reader and inactivates PI3K and MAPK signaling. Co-immunoprecipitation, in vivo and in vitro ubiquitination assays, mass spectrometry (ubiquitination site identification), RNA immunoprecipitation, xenograft mouse model Clinical and translational medicine High 37877353
2023 circNEIL3 (and other circRNAs) stabilize IGF2BP3 protein by preventing HECTD4-mediated ubiquitination; this protects IGF2BP3 from proteasomal degradation in glioma cells. RNA pull-down, mass spectrum, RNA immunoprecipitation (RIP), co-immunoprecipitation assays Molecular cancer Medium 35031058
2023 circNFATC3 binds to IGF2BP3 and prevents TRIM25-mediated ubiquitination, thereby enhancing IGF2BP3 protein stability and enabling it to promote CCND1 mRNA stability in gastric cancer cells. RIP, RNA-FISH/IF, IP, rescue experiments, co-immunoprecipitation Journal of translational medicine Medium 37340423
2023 IGF2BP3 enhances translational efficiency of COPS7B mRNA to promote colorectal cancer growth and metastasis; COPS7B interacts with ribosomes to facilitate ribosome biogenesis and mRNA translation initiation. RIP-seq, ribosome-protected mRNA analysis (ribosome profiling), proteomics, functional assays Cancer research Medium 37560971
2024 IGF2BP3 preferentially binds internal mRNA m7G modifications and, unlike its m6A-binding activity which stabilizes transcripts, IGF2BP3-m7G interaction promotes degradation of m7G-modified target transcripts including TP53 in cancer cells. In vitro binding assays, m7G modification assays, IGF2BP3 knockdown/modulation, dCas13b-guided site-specific m7G targeting, mRNA half-life measurements Nature communications High 39198433
2024 Lysine lactylation of IGF2BP3 (driven by increased glycolysis/lactate accumulation) is required for capturing PCK2 and NRF2 mRNAs, enhancing their expression and reprogramming serine metabolism; this lactylated IGF2BP3-PCK2-SAM-m6A loop promotes lenvatinib resistance in HCC. Lactylation modification assays, RIP assays, in vitro and in vivo lenvatinib-resistant models, siRNA liposome delivery Advanced science Medium 39450426
2023 IGF2BP3 binds to the 3'-UTR of COX6B2 mRNA in an m6A-dependent manner to increase COX6B2 mRNA stability, promoting oxidative phosphorylation and EGFR-TKI resistance in non-small cell lung cancer. RIP, MeRIP, mRNA stability assays, in vitro/in vivo EGFR-TKI resistance models, patient-derived xenograft Cancer research High 37061993
2023 IGF2BP3 binds m6A-modified MCM5 mRNA to prolong its stability, upregulating MCM5 protein which competitively inhibits SIRT1-mediated deacetylation of Notch1 intracellular domain (NICD1), stabilizing NICD1 and activating Notch signaling to promote partial EMT in lung adenocarcinoma. MeRIP-seq, RIP, mRNA stability assay, co-immunoprecipitation, in vitro and in vivo functional assays, clinical LUAD specimen correlation Advanced science Medium 37171793
2022 IGF2BP3 binds to and stabilizes m6A-modified NRF2 mRNA (identified by RIP and RNA pulldown), preventing ferroptosis in hepatocellular carcinoma; IGF2BP3 knockdown promoted ferroptosis and sensitized HCC cells to sorafenib. RIP, RNA pulldown, m6A reader activity assay, ferroptosis markers (ROS, Fe2+, MDA), in vivo experiments Biochemical and biophysical research communications Medium 36030651
2022 IGF2BP3 binds to and stabilizes m6A-modified mRNAs of anti-ferroptotic factors (GPX4, SLC3A2, ACSL3, FTH1) in an m6A reading domain-dependent manner in lung adenocarcinoma, desensitizing cells to ferroptosis. RIP, MeRIP, mRNA stability assay, IGF2BP3 overexpression, correlation in clinical LUAD specimens Materials today. Bio Medium 36457846
2023 IGF2BP3 stabilizes MMP3 mRNA through interaction with N6-methyladenosine modification; IGF2BP3 expression is upregulated after cardiac injury and both gain- and loss-of-function analyses show it regulates cardiomyocyte proliferation in vitro and in vivo, promoting cardiac regeneration after myocardial infarction. RIP, m6A modification assays, gain/loss-of-function in mouse myocardial infarction model, cardiomyocyte proliferation assays Cell death discovery Medium 37188676
2024 IGF2BP3 stabilizes GLI2 mRNA by targeting its m6A site; stabilized GLI2 then transcriptionally promotes SYVN1, which ubiquitinates and degrades PPARα, inhibiting PPARα-mediated autophagy and exacerbating liver injury in sepsis. RIP, m6A assays, ChIP-qPCR, knockdown experiments in vitro and in cecal ligation and puncture mouse model iScience Medium 38799573
2024 IGF2BP3 recognizes m6A on mRNAs of key serine synthesis pathway genes (ATF4, PHGDH, PSAT1), stabilizing these transcripts to sustain serine production; IGF2BP3 silencing combined with dietary serine/glycine restriction potently inhibits AML in vitro and in vivo while sparing normal hematopoiesis. CRISPR/Cas9 screen, RIP, mRNA stability assays, dietary restriction mouse models, AML in vivo experiments Nature communications High 40328743
2024 IGF2BP3 promotes CAMK1 mRNA stability via m6A modification (MeRIP and RIP assays); IGF2BP3-CAMK1 axis inhibits mitochondrial fission to alleviate diabetic nephropathy progression in vitro and in vivo. MeRIP assay, RIP assay, dual-luciferase reporter, actinomycin D mRNA stability assay, CAMK1 conditional KO mice, STZ diabetic mouse model Biochimica et biophysica acta. Molecular basis of disease Medium 38216068
2024 IGF2BP3 recognizes m6A modification on HIF1A mRNA, increasing HIF1A RNA stability and expression; stabilized HIF1A activates RhoA/YAP signaling to promote hepatocyte reprogramming in acute-on-chronic liver failure. m6A dot assay, m6A-antibody precipitation PCR, overexpression and knockdown in HepG2/Hep3B cells, EdU staining, sphere formation assay Cellular signalling Medium 37257765
2024 WTAP-mediated m6A modification of ULK1 mRNA is recognized and stabilized by IGF2BP3 in an m6A-dependent manner, leading to elevated ULK1 expression and enhanced mitophagy in epithelial ovarian cancer. MeRIP assay, RIP assay, knockdown/overexpression, in vitro and in vivo functional assays Cell death & disease Medium 38286802
2024 IGF2BP3 enhances mRNA stability of HMGB1 by binding to its mRNA (RIP assay), promoting inflammation and bladder cancer progression; pharmacological inhibition of HMGB1 reverses IGF2BP3 overexpression-induced cancer-promoting effects. RNA immunoprecipitation (RIP), mRNA stability assays, proliferation/migration/invasion assays, xenograft model Cellular & molecular biology letters Medium 38504159
2024 IGF2BP3 interacts with MYLK mRNA in an m6A-dependent manner, extending its half-life and inhibiting ERK1/2 phosphorylation, thereby repressing MSC adipogenesis; IGF2BP3 overexpression via AAV in adipose tissue reduced body weight and improved insulin resistance in high-fat diet mice. RIP, m6A interaction assay, mRNA half-life assay, MSC differentiation assays, AAV-mediated overexpression in mice Cellular and molecular life sciences Medium 38196046
2024 IGF2BP3 enhances RRM2 mRNA stability by reading its m6A modification (MeRIP assay), promoting HCC cell malignant behaviors and M2 macrophage polarization by suppressing ferroptosis; FOXM1 is an upstream transcriptional activator of IGF2BP3 (ChIP + dual-luciferase). MeRIP, RIP, ChIP, dual-luciferase reporter, Co-IP, ferroptosis assays (MDA, GSH, ROS, lipid ROS), flow cytometry, xenograft model Molecular and cellular biochemistry Medium 39630361
2023 IGF2BP3 promotes m6A-dependent stabilization of EGFR mRNA in cooperation with METTL14, activating the EGFR pathway and mediating cetuximab resistance in colorectal cancer. MeRIP, RIP, mRNA stability assay, co-immunoprecipitation with METTL14, functional assays, in vivo tumor models Cell death & disease Medium 37658049
2022 IGF2BP3 binds to and destabilizes m6A-methylated SLIT2 mRNA in triple-negative breast cancer, impairing SLIT2/ROBO1 signaling and triggering activation of PI3K/AKT and MEK/ERK pathways to promote metastasis. RIP, MeRIP, mRNA stability assay, in vivo metastasis model, functional migration/invasion assays FASEB journal Medium 36250924
2023 IGF2BP3 regulates NFAT1 mRNA stability and translation in an m6A-dependent manner; NFAT1 induced by IGF2BP3 acts as a transcription factor to suppress IRF1 expression, inactivating interferon signaling and promoting gastric cancer progression. Ribo-seq, RNA-seq, m6A-seq, gain/loss-of-function experiments, mRNA stability assays Cell death & disease Medium 38448411
2023 In neuroblastoma, IGF2BP3 and MYCN form a positive feedback loop: IGF2BP3 stabilizes MYCN mRNA via m6A modification, while MYCN acts as a transcription factor that directly promotes IGF2BP3 expression. RIP, MeRIP, ChIP assays, knockdown/overexpression in vitro and in vivo Cell death discovery Medium 37156775
2023 circRARS binds to KH1-KH2 domains of IGF2BP3 (12-nt sequence GUCUUCCAGCAA identified as binding site), enhancing m6A modification recognition; the IGF2BP3/circRARS complex stabilizes target mRNAs (CAPN15, CD44, HMGA2, TNRC6A, ZMIZ2) by recruiting stabilizer proteins HuR, Matrin3, and pAbPC1. RIP, RNA pull-down, domain mapping, mRNA stability assays, co-immunoprecipitation, in vitro and in vivo experiments Clinical and translational medicine Medium 38073586
2024 WTAP-mediated m6A modification of GBE1 mRNA is stabilized by IGF2BP3 through RIP-confirmed interaction; WTAP/IGF2BP3 axis increases GBE1 mRNA stability and expression to promote pancreatic cancer cell proliferation and stemness via c-Myc. RIP assay, RNA stability experiments, Western blot, functional assays, subcutaneous/orthotopic mouse models Cellular & molecular biology letters Medium 38961325
2024 IGF2BP3 upregulation in glioma enhances expression of E3 ubiquitin ligase MIB1, promoting FTO degradation via the ubiquitin-proteasome pathway, resulting in increased m6A-mediated CSF3 release and NET formation (NETosis); BET inhibitor reduces IGF2BP3 expression via BRD4/CDK9/RPB-1. IGF2BP3 overexpression/knockdown, ubiquitin-proteasome pathway assays, m6A assays, in vivo glioma models Nature communications Medium 38167409
2024 WTAP-mediated m6A modification of EGR1 mRNA requires IGF2BP3 as a reader for recognition and stability; loss of WTAP decreases m6A on EGR1 mRNA, reducing IGF2BP3 binding and EGR1 mRNA stability, leading to decreased PTEN expression and promoting endometrial cancer stem cell traits. m6A modification assays, RIP, Western blot, gain-of-function rescue experiments in vivo Journal of experimental & clinical cancer research Medium 39044249
2024 IGF2BP3 deficiency in hepatic stellate cells reduces m6A content in Jagged1 (Jag1) mRNA, decreasing Notch/Hes1 signaling and GPX4 levels, thereby promoting ferroptosis in HSCs and reducing liver fibrosis. IGF2BP3 knockout mouse, multi-omics analysis, m6A quantification of Jag1, in vitro and in vivo ferroptosis assays Clinical and translational medicine Medium 39113232
2024 IGF2BP3 promotes LDHA mRNA stability via m6A binding (RIP confirmed), increasing lactate accumulation and impairing CD8+ T cell anti-tumor immunity in gastric cancer. RIP, mRNA stability assay, co-culture system with CD8+ T cells, functional assays Apoptosis Medium 39397122
2023 IGF2BP3 promotes m6A-dependent stabilization of SENP1 mRNA (3'UTR binding confirmed by MERIP-qPCR and RIP-qPCR), enhancing SENP1 expression which de-SUMOylates HDAC2 to activate EGFR transcription and the AKT pathway in AML. MERIP-qPCR, RIP-qPCR, CO-IP, RNA pulldown, dual-luciferase reporter, ChIP-qPCR Molecular cancer Medium 38822351
2025 IGF2BP3 binds to m6A-modified RASGRF1 mRNA to stabilize it, activating mTORC1 signaling in RA fibroblast-like synoviocytes; IGF2BP3 knockout in mice ameliorated arthritis joint injury and reduced inflammatory infiltration. RIP, MeRIP, IGF2BP3 KO mouse arthritis model (K/BxN serum transfer), transfection experiments Bone research Medium 40355406
2023 IGF2BP3 promotes m6A-dependent stabilization of CLDN4 mRNA in gallbladder cancer, activating NF-κB signaling; overexpression of IGF2BP3 also promotes M2 macrophage polarization via upregulation of STAT3. RIP, mRNA stability assay, knockdown/overexpression, in vitro/in vivo functional assays, macrophage co-culture Translational oncology Medium 37643553
2024 NONO synergizes with IGF2BP3 (m6A reader) to promote exon6 skipping in DLG1 in an m6A-dependent manner in gallbladder cancer; IP/MS showed RBM14 binds NONO and interferes with NONO-mediated skipping, while IGF2BP3 disrupts the RBM14-NONO interaction. RIP-seq, mRNA-seq, IP/MS, Co-IP, alternative splicing (PSI) analysis Cancer letters Medium 38341127
2023 Berberine promotes TRIM21-mediated ubiquitination of IGF2BP3 (Co-IP), reducing its stability; this inhibits IGF2BP3-mediated stabilization of CDK4/CCND1 mRNA (RIP assay) and promotes G1/S phase arrest in colorectal cancer. Co-immunoprecipitation, RIP assay, CETSA, DARTS, in vivo mouse model Chemico-biological interactions Medium 36822301
2024 IGF2BP3 enhances the stability and expression of MDM2 mRNA through m6A-dependent binding (MeRIP and RIP assays), promoting AML cell proliferation and ferroptosis resistance; Licochalcone A suppresses this axis affecting the MDM2/p53 pathway. MeRIP assay, RIP assay, actinomycin D mRNA stability, xenograft model, ferroptosis assays Annals of hematology Medium 39264435
2024 IGF2BP3 enhances DDX21 mRNA stability in an m6A-dependent manner (MeRIP + RIP + luciferase reporter) in AML, driven by super-enhancer (SE)-associated IGF2BP3 expression; DDX21 recruits transcription factor YBX1 to cooperatively trigger ULK1 expression. MeRIP assay, RIP assay, luciferase reporter assay, ChIP-seq (SE identification), Co-IP, RNA-seq, in vivo AML model Clinical and translational medicine Medium 38572589
2020 IGF2BP3 activates the JAK/STAT signaling pathway in bladder cancer cells; IGF2BP3 knockdown suppressed proliferation and JAK/STAT activation, while JAK/STAT inhibitor blocked IGF2BP3 tumor-promoting activity. Overexpression/knockdown, cell proliferation, cell cycle and apoptosis assays, JAK/STAT inhibitor treatment, in vivo tumor model Journal of cellular and molecular medicine Low 33094561
2020 IGF2BP3 increases HCC cell invasiveness by binding to the 3'UTR of ZO-1 mRNA (directly shown) and promoting formation of an miR-191-5p-induced RNA-induced silencing complex, suppressing ZO-1 expression. 3'UTR binding assay, RIP, miR-191-5p inhibitor experiments, invasion assays Oncology letters Low 32724385
2024 IGF2BP3 promotes IGF2BP3-mediated stabilization of SERPINE1 mRNA (by RIP) in HNSCC; circPRMT5 binds to and stabilizes IGF2BP3 protein, and the IGF2BP3-SERPINE1 axis mediates circPRMT5-driven proliferation and metastasis. RIP, RNA-FISH, immunofluorescence, Western blot, rescue experiments International journal of nanomedicine Medium 39931528
2022 IGF2BP3 regulates SCD mRNA m6A modification via an IGF2BP3-METTL14 complex, enhancing SCD mRNA stability and promoting lipid metabolism, proliferation, and metastasis of cervical cancer. RIP, MeRIP, RNA-seq, knockdown/overexpression, in vitro/in vivo tumor assays Cell death & disease Medium 38355626
2023 MYC transcriptionally activates IGF2BP3 by binding to its promoter (confirmed by luciferase assay and ChIP); IGF2BP3 then stabilizes KPNA2 mRNA via m6A modification in nasopharyngeal carcinoma. Luciferase assay, ChIP assay, MeRIP, mRNA stability assay Cell death discovery Medium 35136045
2022 IGF2BP3 binds and stabilizes TMBIM6 mRNA in an m6A-dependent manner (RBM15 as the writer); this stabilization was confirmed by actinomycin D mRNA decay assay and RNase MazF-based methylation site assay in laryngeal squamous cell carcinoma. RIP, MeRIP-seq, RNase MazF, actinomycin D mRNA stability assay, luciferase reporter, in vitro/in vivo assays Journal of experimental & clinical cancer research Medium 33637103
2022 circARID1A serves as a scaffold to facilitate the interaction between IGF2BP3 and SLC7A5 mRNA, increasing SLC7A5 mRNA stability; circARID1A also directly binds SLC7A5 mRNA, forming a circARID1A-IGF2BP3-SLC7A5 ternary complex promoting gastric cancer proliferation via AKT/mTOR pathway. RNA pull-down, RIP-seq, RIP, RNA-FISH/IF, in vitro/in vivo functional assays Journal of experimental & clinical cancer research Medium 35986300
2024 circABCA1 forms a ternary complex with IGF2BP3 and SCARB1 mRNA to enhance SCARB1 mRNA stability, increasing cholesterol uptake; this promotes lipid raft maintenance, IGF1R/PI3K/AKT/mTOR activation, and M2 macrophage polarization in ccRCC. MS2 RNA-pulldown, RNA immunoprecipitation, RNA-FISH, lipid/cholesterol assays, co-culture system, xenograft models Molecular cancer Medium 40684174

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2003 Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2521 14671650
2022 METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N6-methyladenosine modification of PD-L1 mRNA in breast cancer. Molecular cancer 352 35197058
2022 EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3. Molecular cancer 263 35031058
2014 The role of the oncofetal IGF2 mRNA-binding protein 3 (IGF2BP3) in cancer. Seminars in cancer biology 238 25068994
2020 RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. Journal of experimental & clinical cancer research : CR 230 32993738
2006 Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 214 17170731
2021 RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. Journal of experimental & clinical cancer research : CR 207 33637103
2006 Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. Leukemia 181 17170730
2016 RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation. The Journal of clinical investigation 141 26974154
2022 Hsa_circ_0003258 promotes prostate cancer metastasis by complexing with IGF2BP3 and sponging miR-653-5p. Molecular cancer 131 34986849
2020 IGF2BP3 From Physiology to Cancer: Novel Discoveries, Unsolved Issues, and Future Perspectives. Frontiers in cell and developmental biology 129 32010687
2024 Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 124 39450426
2023 Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer. Cancer research 114 37061993
2022 The m6A reader IGF2BP3 promotes acute myeloid leukemia progression by enhancing RCC2 stability. Experimental & molecular medicine 113 35217832
2020 IGF2BP3 facilitates cell proliferation and tumorigenesis via modulation of JAK/STAT signalling pathway in human bladder cancer. Journal of cellular and molecular medicine 101 33094561
2020 circIGHG-Induced Epithelial-to-Mesenchymal Transition Promotes Oral Squamous Cell Carcinoma Progression via miR-142-5p/IGF2BP3 Signaling. Cancer research 85 33203701
2022 IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells. Materials today. Bio 83 36457846
2022 CircARID1A binds to IGF2BP3 in gastric cancer and promotes cancer proliferation by forming a circARID1A-IGF2BP3-SLC7A5 RNA-protein ternary complex. Journal of experimental & clinical cancer research : CR 77 35986300
2019 Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation. EBioMedicine 77 30797711
2016 IGF2BP3 Modulates the Interaction of Invasion-Associated Transcripts with RISC. Cell reports 72 27210763
2023 A circular RNA activated by TGFβ promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability. Nature communications 68 37898647
2019 Increased IGF2BP3 expression promotes the aggressive phenotypes of colorectal cancer cells in vitro and vivo. Journal of cellular physiology 62 30895618
2015 Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA. Oncogene 62 26522719
2023 m6 A-Dependent Modulation via IGF2BP3/MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 60 37171793
2014 IGF2BP3-mediated translation in cell protrusions promotes cell invasiveness and metastasis of pancreatic cancer. Oncotarget 58 25216519
2022 Isoliquiritigenin inhibits non-small cell lung cancer progression via m6A/IGF2BP3-dependent TWIST1 mRNA stabilization. Phytomedicine : international journal of phytotherapy and phytopharmacology 56 35816995
2024 Overcoming therapeutic resistance in oncolytic herpes virotherapy by targeting IGF2BP3-induced NETosis in malignant glioma. Nature communications 55 38167409
2023 Targeting IGF2BP3 in Cancer. International journal of molecular sciences 55 37298373
2019 Enhancement of LIN28B-induced hematopoietic reprogramming by IGF2BP3. Genes & development 55 31221665
2022 IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma. Biochemical and biophysical research communications 53 36030651
2014 Role of IGF2BP3 in trophoblast cell invasion and migration. Cell death & disease 51 24457969
2020 Igf2bp3 maintains maternal RNA stability and ensures early embryo development in zebrafish. Communications biology 50 32127635
2022 MYC-activated RNA N6-methyladenosine reader IGF2BP3 promotes cell proliferation and metastasis in nasopharyngeal carcinoma. Cell death discovery 48 35136045
2017 Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. The Journal of clinical investigation 48 28481226
2024 IGF2BP3 promotes mRNA degradation through internal m7G modification. Nature communications 46 39198433
2023 CircNFATC3 promotes the proliferation of gastric cancer through binding to IGF2BP3 and restricting its ubiquitination to enhance CCND1 mRNA stability. Journal of translational medicine 46 37340423
2023 IGF2BP3 promotes the progression of colorectal cancer and mediates cetuximab resistance by stabilizing EGFR mRNA in an m6A-dependent manner. Cell death & disease 44 37658049
2024 N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2. Molecular cancer 43 38822351
2021 CircRNA circFOXK2 facilitates oncogenesis in breast cancer via IGF2BP3/miR-370 axis. Aging 43 34329193
2009 IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Human pathology 40 19698973
2021 The RNA-binding protein IGF2BP3 is critical for MLL-AF4-mediated leukemogenesis. Leukemia 39 34321607
2023 IGF2BP3 Regulates TMA7-mediated Autophagy and Cisplatin Resistance in Laryngeal Cancer via m6A RNA Methylation. International journal of biological sciences 33 37056932
2024 IGF2BP3 enhances lipid metabolism in cervical cancer by upregulating the expression of SCD. Cell death & disease 31 38355626
2022 RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 30 36250924
2024 WTAP/IGF2BP3 mediated m6A modification of the EGR1/PTEN axis regulates the malignant phenotypes of endometrial cancer stem cells. Journal of experimental & clinical cancer research : CR 29 39044249
2023 The IGF2BP3-COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression. Cancer research 28 37560971
2024 IGF2BP3 prevent HMGB1 mRNA decay in bladder cancer and development. Cellular & molecular biology letters 27 38504159
2020 Hsa_circ_0026134 expression promoted TRIM25- and IGF2BP3-mediated hepatocellular carcinoma cell proliferation and invasion via sponging miR-127-5p. Bioscience reports 27 32648571
2011 Oncofetal protein, IMP-3, a potential marker for prediction of postoperative peritoneal dissemination in gastric adenocarcinoma. Journal of surgical oncology 27 22012575
2023 IGF2BP3 promotes adult myocardial regeneration by stabilizing MMP3 mRNA through interaction with m6A modification. Cell death discovery 25 37188676
2023 Expression pattern analysis of m6A regulators reveals IGF2BP3 as a key modulator in osteoarthritis synovial macrophages. Journal of translational medicine 24 37217897
2024 Regulation of ULK1 by WTAP/IGF2BP3 axis enhances mitophagy and progression in epithelial ovarian cancer. Cell death & disease 23 38286802
2021 IGF2BP3 promotes cell metastasis and is associated with poor patient survival in nasopharyngeal carcinoma. Journal of cellular and molecular medicine 23 34894048
2020 IGF2BP3 and miR191-5p synergistically increase HCC cell invasiveness by altering ZO-1 expression. Oncology letters 23 32724385
2024 The RNA m6A reader IGF2BP3 regulates NFAT1/IRF1 axis-mediated anti-tumor activity in gastric cancer. Cell death & disease 22 38448411
2015 Expression of the cancer testis antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific immunotherapy target. Oncoscience 22 26244168
2009 IMP-3 expression in melanocytic lesions. Journal of cutaneous pathology 22 19788446
2024 The IGF2BP3/Notch/Jag1 pathway: A key regulator of hepatic stellate cell ferroptosis in liver fibrosis. Clinical and translational medicine 21 39113232
2024 IGF2BP3 boosts lactate generation to accelerate gastric cancer immune evasion. Apoptosis : an international journal on programmed cell death 21 39397122
2023 circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma. Clinical and translational medicine 21 38073586
2024 m6A-dependent upregulation of DDX21 by super-enhancer-driven IGF2BP2 and IGF2BP3 facilitates progression of acute myeloid leukaemia. Clinical and translational medicine 20 38572589
2023 Parkin regulates IGF2BP3 through ubiquitination in the tumourigenesis of cervical cancer. Clinical and translational medicine 20 37877353
2023 RNA N6-methyladenosine reader IGF2BP3 interacts with MYCN and facilitates neuroblastoma cell proliferation. Cell death discovery 19 37156775
2025 CircABCA1 promotes ccRCC by reprogramming cholesterol metabolism and facilitating M2 macrophage polarization through IGF2BP3-mediated stabilization of SCARB1 mRNA. Molecular cancer 18 40684174
2024 WTAP/IGF2BP3-mediated GBE1 expression accelerates the proliferation and enhances stemness in pancreatic cancer cells via upregulating c-Myc. Cellular & molecular biology letters 18 38961325
2023 Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer. Frontiers in immunology 18 36761737
2023 Berberine promotes IGF2BP3 ubiquitination by TRIM21 to induce G1/S phase arrest in colorectal cancer cells. Chemico-biological interactions 18 36822301
2024 Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia. Blood advances 17 38048400
2023 IGF2BP3 Worsens Lung Cancer through Modifying Long Non-coding RNA CERS6-AS1/microRNA-1202 Axis. Current medicinal chemistry 17 35702784
2023 U-shaped association between serum IGF2BP3 and T2DM: A cross-sectional study in Chinese population. Journal of diabetes 17 36891946
2021 LINC00460 facilitated tongue squamous cell carcinoma progression via the miR-320b/IGF2BP3 axis. Oral diseases 17 33660359
2023 IGF2BP3 drives gallbladder cancer progression by m6A-modified CLDN4 and inducing macrophage immunosuppressive polarization. Translational oncology 16 37643553
2025 RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer. Journal of translational medicine 15 39962467
2025 m6A/IGF2BP3-driven serine biosynthesis fuels AML stemness and metabolic vulnerability. Nature communications 14 40328743
2024 IGF2BP3-stabilized CAMK1 regulates the mitochondrial dynamics of renal tubule to alleviate diabetic nephropathy. Biochimica et biophysica acta. Molecular basis of disease 14 38216068
2024 FOXM1-activated IGF2BP3 promotes cell malignant phenotypes and M2 macrophage polarization in hepatocellular carcinoma by inhibiting ferroptosis via stabilizing RRM2 mRNA in an m6A-dependent manner. Molecular and cellular biochemistry 14 39630361
2024 m6A-modified circCREBBP enhances radiosensitivity of esophageal squamous cell carcinoma by reducing the stability of MYC through interaction with IGF2BP3. International journal of biological macromolecules 14 39653202
2025 IGF2BP3-mediated m6A modification of RASGRF1 promoting joint injury in rheumatoid arthritis. Bone research 13 40355406
2024 IGF2BP3-mediated enhanced stability of MYLK represses MSC adipogenesis and alleviates obesity and insulin resistance in HFD mice. Cellular and molecular life sciences : CMLS 13 38196046
2023 UBE2K regulated by IGF2BP3 promotes cell proliferation and stemness in pancreatic ductal adenocarcinoma. International journal of oncology 13 36896783
2023 IGF2BP3/HIF1A/YAP signaling plays a role in driving acute-on-chronic liver failure through activating hepatocyte reprogramming. Cellular signalling 13 37257765
2021 The RNA-binding protein Igf2bp3 is critical for embryonic and germline development in zebrafish. PLoS genetics 13 34214072
2015 EGF enhances low-invasive cancer cell invasion by promoting IMP-3 expression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 13 26386725
2024 Licochalcone A decreases cancer cell proliferation and enhances ferroptosis in acute myeloid leukemia through suppressing the IGF2BP3/MDM2 cascade. Annals of hematology 12 39264435
2023 IGF2BP3-EGFR-AKT axis promotes breast cancer MDA-MB-231 cell growth. Biochimica et biophysica acta. Molecular cell research 12 37474008
2023 METTL3/IGF2BP3-regulated m6A modification of HYOU1 confers doxorubicin resistance in breast cancer. Biochimica et biophysica acta. General subjects 12 38103759
2022 hsa_circ_0000231 Promotes colorectal cancer cell growth through upregulation of CCND2 by IGF2BP3/miR-375 dual pathway. Cancer cell international 12 35033075
2020 The Aberrant Expression of MicroRNA-125a-5p/IGF2BP3 Axis in Advanced Gastric Cancer and Its Clinical Relevance. Technology in cancer research & treatment 12 32266868
2016 IMP-3 protects the mRNAs of cyclins D1 and D3 from GW182/AGO2-dependent translational repression. International journal of oncology 12 27840950
2024 NONO promotes gallbladder cancer cell proliferation by enhancing oncogenic RNA splicing of DLG1 through interaction with IGF2BP3/RBM14. Cancer letters 11 38341127
2024 IGF2BP3 regulates the expression of RRM2 and promotes the progression of rheumatoid arthritis via RRM2/Akt/MMP-9 pathway. PloS one 11 38820515
2024 Epigenetically associated IGF2BP3 upregulation promotes cell proliferation by regulating E2F1 expression in hepatocellular carcinoma. Scientific reports 11 38992083
2023 IGF2BP3 aggravates lung adenocarcinoma progression by modulation of PI3K/AKT signaling pathway. Immunopharmacology and immunotoxicology 11 36972188
2023 RNA N6-methyladenosine reader IGF2BP3 promotes acute myeloid leukemia progression by controlling stabilization of EPOR mRNA. PeerJ 11 37663284
2020 IGF2BP3 (IMP3) expression in angiosarcoma, epithelioid hemangioendothelioma, and benign vascular lesions. Diagnostic pathology 11 32293476
2025 CircPRMT5, a Potential Salivary Biomarker, Facilitates the Progression of Head and Neck Squamous Cell Carcinoma via the IGF2BP3-SERPINE1 Pathway. International journal of nanomedicine 10 39931528
2024 IGF2BP3 loss inhibits cell progression by upregulating has_circRNA_103820, and hsa_circRNA_103820-encoded peptide inhibits cell progression by inactivating the AKT pathway in lung cancer. Chemical biology & drug design 10 38378275
2024 IGF2BP3 modified GLI2 transcriptionally regulates SYVN1 and facilitates sepsis liver injury through autophagy. iScience 10 38799573
2024 IGF2BP3 promotes glutamine metabolism of endometriosis by interacting with UCA1 to enhances the mRNA stability of GLS1. Molecular medicine (Cambridge, Mass.) 9 38760723
2023 Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. Cancer gene therapy 9 37353558

Missed literature

Know a paper Affinage missed for IGF2BP3? Flag it for the maintainers and the community.

No submissions yet.